| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1088 | 2018 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 496 | 2021 |
| Frequency and spectrum of PIK3CA somatic mutations in breast cancer O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, ... Breast cancer research 22, 1-9, 2020 | 323 | 2020 |
| Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label … A Prat, C Saura, T Pascual, C Hernando, M Muñoz, L Paré, BG Farré, ... The lancet oncology 21 (1), 33-43, 2020 | 179 | 2020 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 153 | 2020 |
| Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies A Prat, A Chaudhury, N Solovieff, L Paré, D Martinez, N Chic, ... Journal of Clinical Oncology 39 (13), 1458-1467, 2021 | 128 | 2021 |
| Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ... Nature communications 11 (1), 385, 2020 | 106 | 2020 |
| Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer A Prat, V Guarneri, T Pascual, F Braso-Maristany, E Sanfeliu, L Pare, ... EBioMedicine 75, 2022 | 93 | 2022 |
| Development of a risk prediction score for occult cancer in patients with VTE L Jara-Palomares, R Otero, D Jimenez, M Carrier, I Tzoran, B Brenner, ... Chest 151 (3), 564-571, 2017 | 80 | 2017 |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation A Prat, V Guarneri, L Paré, G Griguolo, T Pascual, MV Dieci, N Chic, ... The Lancet Oncology 21 (11), 1455-1464, 2020 | 74 | 2020 |
| Treatment of right heart thrombi associated with acute pulmonary embolism D Barrios, J Chavant, D Jiménez, L Bertoletti, V Rosa-Salazar, A Muriel, ... The American journal of medicine 130 (5), 588-595, 2017 | 72 | 2017 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021; 7: 1 F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... PUBMED, 0 | 49 | |
| Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative … A Fernandez-Martinez, T Pascual, B Singh, P Nuciforo, NU Rashid, ... JAMA oncology 9 (4), 490-499, 2023 | 45 | 2023 |
| ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer G Griguolo, F Brasó-Maristany, B Gonzalez-Farre, T Pascual, N Chic, ... Cancers 12 (7), 1902, 2020 | 44 | 2020 |
| Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer G Griguolo, G Serna, T Pascual, R Fasani, X Guardia, N Chic, L Paré, ... NPJ Precision Oncology 5 (1), 23, 2021 | 43 | 2021 |
| Gene expression profiles of breast cancer metastasis according to organ site F Brasó‐Maristany, L Paré, N Chic, O Martínez‐Sáez, T Pascual, ... Molecular oncology 16 (1), 69-87, 2022 | 39 | 2022 |
| Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism F Moustafa, MG Pierfranceschi, P Di Micco, E Bucherini, A Lorenzo, ... Research and practice in thrombosis and haemostasis 1 (2), 172-179, 2017 | 39 | 2017 |
| Successful treatment with gefitinib in advanced non–small cell lung cancer after acquired resistance to osimertinib N Chic, C Mayo-de-Las-Casas, N Reguart Journal of Thoracic Oncology 12 (6), e78-e80, 2017 | 34 | 2017 |
| Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer A Prat, F Brasó-Maristany, O Martínez-Sáez, E Sanfeliu, Y Xia, M Bellet, ... Nature communications 14 (1), 1157, 2023 | 32 | 2023 |
| PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with … V Guarneri, MV Dieci, G Bisagni, AA Brandes, A Frassoldati, L Cavanna, ... Clinical Cancer Research 26 (22), 5843-5851, 2020 | 24 | 2020 |
